Teriflunomide
- Generic Name
- Teriflunomide
- Brand Names
- Aubagio, Teriflunomide Accord, Teriflunomide Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 163451-81-8
- Unique Ingredient Identifier
- 1C058IKG3B
- Background
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patie...
- Indication
Used in the treatment of relapsing forms of multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
- Associated Therapies
- -
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 4000
- Registration Number
- NCT06705608
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2500
- Registration Number
- NCT06372145
- Locations
- 🇺🇸
Springfield Clinic 1st - 800 Building- Site Number : 8400071, Springfield, Illinois, United States
🇺🇸Hope Neurology- Site Number : 8409904, Knoxville, Tennessee, United States
🇺🇸Neurology Center of San Antonio- Site Number : 8400036, San Antonio, Texas, United States
Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06190145
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06176911
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06176235
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama, United States
🇺🇸North Central Neurology Associates- Site Number : 8401100, Cullman, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center- Site Number : 8401139, Phoenix, Arizona, United States
An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 336
- Registration Number
- NCT05385744
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05156281
- Locations
- 🇺🇸
Mayo Clinic Jacksonville ., Jacksonville, Florida, United States
🇺🇸Ctr for Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Vladimir Royter MD APMC, Hanford, California, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05147220
- Locations
- 🇺🇸
Homestead Assoc In Research Inc, Homestead, Florida, United States
🇺🇸NYU Langone Health Research, Brooklyn, New York, United States
🇺🇸AZ Integrated Neuro and Spine Integrated MS Center, Phoenix, Arizona, United States
Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 24
- Registration Number
- NCT04799288
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.